1,423 results match your criteria: ""Magna Graecia" University Hospital[Affiliation]"
Children (Basel)
July 2024
Division of Paediatric Cardiology, Department of Women and Children's Health, University Hospital of Padua, 35128 Padua, Italy.
Congenital heart diseases (CHDs) represent a heterogeneous group of congenital defects, with high prevalence worldwide. Non-invasive imaging is essential to guide medical and surgical planning, to follow the patient over time in the evolution of the disease, and to reveal potential complications of the chosen treatment. The application of cardiac magnetic resonance imaging (CMRI) in this population allows for obtaining detailed information on the defects without the necessity of ionizing radiations.
View Article and Find Full Text PDFCells
July 2024
Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy.
Health Sci Rep
July 2024
Cardio‑thoracic Anaesthesia and Intensive Care Unit University of Verona, AOUI‑University Hospital Integrated Trust of Verona Verona Italy.
Front Endocrinol (Lausanne)
July 2024
Global Medical Affairs, Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.
Introduction: To analyse the perspectives of healthcare professionals (HCPs) regarding the acceptance of digital health solutions for growth hormone (GH) deficiency care. This study identified factors impacting HCPs' intent to use and recommend digital solutions supporting recombinant-human growth hormone (r-hGH) therapy in Italy and Korea with a use case of connected drug delivery system (Aluetta with Smartdot™) integrated in a platform for GH treatment support (the Growzen™ digital health ecosystem).
Methods: Participatory workshops were conducted in Rome, Italy, and Seoul, Korea, to collect the perspectives of 22 HCPs on various predefined topics.
Clin Res Cardiol
July 2024
Division of Cardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
J Cardiovasc Pharmacol
October 2024
Department of Emergency, Internal Medicine and Cardiology, Division of Cardiology, S. Maria delle Croci Hospital, Ravenna, Italy.
Br J Oral Maxillofac Surg
September 2024
Multidisciplinary Department of Medical-Surgical and Dental Specialties, Oral and Maxillofacial Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
With the increasing use of sustainable energy sources, the electric scooter has become a widely used vehicle. The aim of the study is to analyse the types of facial fracture related to road traffic accidents to outline the need for dedicated road rules. An observational, retrospective, multicentre study was carried out at the Maxillofacial Surgery Units of six Italian hospitals.
View Article and Find Full Text PDFDiabetes Res Clin Pract
August 2024
Section of Endocrinology and Diabetes, Bianchi Melacrino Morelli Hospital, Reggio Calabria, Italy; AMD Annals Initiative, AMD Foundation, Rome, Italy.
Aims: Describing the evolution over time in the use of sulfonylureas (SUs) and the characteristics of patients at first prescription and at interruption of treatment with SUs.
Methods: Retrospective evaluation of data from the Italian Association of Diabetologists (AMD) Annals registry (2010-2020), about T2D patients who started treatment with SUs. The longitudinal probability of remaining on SUs was estimated by Kaplan Meier survival curves.
Infect Dis Ther
September 2024
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Front Psychol
June 2024
Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Background: Metacognition is a crucial aspect of understanding and attributing mental states, playing a key role in the psychopathology of eating disorders (EDs). This study aims to explore the diverse clinical profiles of metacognition among patients with EDs using latent profile analysis (LPA).
Method: A total of 395 patients with a DSM-5 diagnosis of ED (116 AN-R, 30 AN/BP, 100 BN, 149 BED) participated in this study.
Int J Cardiol
October 2024
Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Neurology
August 2024
From the Université Paris-Saclay (C.D., P.-E.S., B.P., A.E.), UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France; Centre for Genetic Epidemiology (A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, and Department for Neurodegenerative Diseases (C.S., K.B., T.G.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., K.B., T.G.), Tubingen; Center for Human Genetics (S.G.), Universitatsklinikum Giessen und Marburg, Germany; Department of Public Health (P.-C.L.), National Cheng Kung University, Tainan, Taiwan; Translational Neuroscience (P.M., D.B., R.K.), Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Molecular Genetics Section (A.B.S., D.H., C.E.), Laboratory of Neurogenetics, and Center for Alzheimer's and Related Dementias (A.B.S.), NIA, NIH, Bethesda, MD; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Nathan, Australia; Department of Neurology (A.A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Tanz Centre for Research in Neurodegenerative Diseases (E.A.R., A.E.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.E.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.E.L.), University of Toronto; Krembil Brain Institute (A.E.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic (P.T.), Tartu University Hospital, Estonia; Department of Neurologie (S.L., A.B., J.-C.C.), Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université; Assistance Publique Hôpitaux de Paris (J.-C.C.), Department of Neurology, CIC Neurosciences; Univ. Lille (M.-C.C.-H., E.M.), Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Greece; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia; 1st Department of Neurology (L. Stefanis, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens; Center of Clinical Research, Experimental Surgery and Translational Research (L. Stefanis), Biomedical Research Foundation of the Academy of Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital, Rome; Department of Clinical and Molecular Medicine (S.P.), University of Rome; Department of Biomedical Sciences (L. Straniero), Humanitas University, Milan; Parkinson Institute (A.L.Z.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano; Parkinson Institute (G.P.), Fontazione Grigioni-Via Zuretti, Milan; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Monza; Department of Medicine and Surgery and Milan Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Milano; Institute for Biomedical Research and Innovation (G.A.), National Research Council, Cosenza; Institute of Neurology (A.Q.), Magna Graecia University; Institute of Molecular Bioimaging and Physiology National Research Council (M.G.), Catanzaro, Italy; Department of Integrative Physiology and Bio-Nano Medicine (H.M., A.N.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Neurology (P.K., R.K.), Centre Hospitalier de Luxembourg; Department of Neurology (B.P.C.V.D.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Radboud University Medical Centre, the Netherlands; Department of Neurology (M.T., L.P.), Oslo University Hospital, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit (E.T.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) (E.T.); Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.-F.), Terrassa; Movement Disorders Unit (P.P., M.D.-F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), and Department of Neuroscience (C.R., A.C.B.), Karolinska Institutet, Stockholm; Department of Clinical Sciences Lund (A.P., C.H.), Neurology, Skåne University Hospital, Lund University, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine (K.E.M.), Health and Life Sciences, Queens University, Belfast; Department of Clinical and Movement Neurosciences (M.M.T.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology (D.K., L.F.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.); German Center for Neurodegenerative Diseases (DZNE) (L.F.B.), Munich, Germany; Department of Neurology (M.F.), McKnight Brain Institute, University of Florida, Gainesville; Parkinson's Research Clinic (R.K.), Centre Hospitalier de Luxembourg; and Transversal Translational Medicine (R.K.), Luxembourg Institute of Health (LIH), Strassen.
Front Neurol
June 2024
Department of Science of Health, School of Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Background: The primary aims of our cross-sectional observational study were: (i) to determine the prevalence of depressive symptoms in children and adolescents with epilepsy compared to controls and (ii) to explore the difference in depressive symptoms in patients with epilepsy only and those with epilepsy and primary headache as a comorbidity. The secondary objective was to explore parental stress levels.
Methods: 68 pediatric patients aged 6-18 years (44 with epilepsy only and 24 with epilepsy and headache) and 50 controls were recruited.
Eur J Intern Med
October 2024
Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Introduction: Patients with chronic obstructive pulmonary disease (COPD) frequently have cardiovascular comorbidities, increasing the risk of hospitalised COPD exacerbations (H-ECOPDs) or death. This pragmatic study examined the effects of adding an inhaled corticosteroid (ICS) to long-acting bronchodilator(s) (LABDs) in patients with COPD and cardiac comorbidities who had a recent H-ECOPD.
Methods: Patients >60 years of age with COPD and ≥1 cardiac comorbidity, within 6 months after discharge following an H-ECOPD, were randomised to receive LABD(s) with or without ICS, and were followed for 1 year.
Eur Arch Otorhinolaryngol
November 2024
Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Purpose: This study introduces and evaluates the sitting lateral canal maneuver (SLCM), a novel seated repositioning technique for treating geotropic lateral canal benign paroxysmal positional vertigo (BPPV).
Methods: We conducted a retrospective chart review at the Hospital of Salerno, focusing on 26 patients diagnosed with geotropic LC-BPPV between 2021 and 2022. The SLCM was applied, and its efficacy was assessed based on the resolution of nystagmus and vertigo symptoms.
ESMO Open
July 2024
Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address:
Background: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis.
Materials And Methods: This was a retrospective, European, multicentre study.
Eur J Med Genet
August 2024
Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.
Background And Objective: X-linked hypophosphatemic rickets (XLH) is due to loss-of-function mutations in the phosphate-regulating endopeptidase homologue on the X chromosome (PHEX) that lead to increased fibroblast growth factor 23 (FGF23) production. FGF23 excess causes renal phosphate wasting and insufficient 1,25-dihydroxyvitamin D (1,25(OH)D) synthesis with reduced intestinal phosphate absorption, ultimately resulting in chronic hypophosphatemia. Children with XLH show typical skeletal lesions of rickets, deformities of the lower limbs, stunted growth with disproportionate short stature, bone pain, and physical dysfunctions.
View Article and Find Full Text PDFWorld J Gastroenterol
June 2024
Science of Health Department, General Surgery Unit, University "Magna Graecia" Medical School, University Hospital "R. Dulbecco", Catanzaro 88100, Italy.
In this editorial, we focus specifically on the mechanisms by which pancreatic inflammation affects pancreatic cancer. Cancer of the pancreas remains one of the deadliest cancer types. The highest incidence and mortality rates of pancreatic cancer are found in developed countries.
View Article and Find Full Text PDFEur Heart J Qual Care Clin Outcomes
September 2024
Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples 80131, Italy.
Aims: The Italian Fabry Disease Cardiovascular Registry (IFDCR) comprises 50 Italian centres with specific expertise in managing cardiovascular manifestations and complications of patients with Fabry disease (FD). The primary aim of the IFDCR is to examine and improve the clinical care and outcomes of patients with FD by addressing several knowledge gaps in the epidemiology, natural history, genotype-phenotype correlations, diagnosis, and management of this condition, with particular focus on cardiovascular manifestations and complications.
Methods And Results: The IFDCR is an international, longitudinal, multicentre, non-interventional, observational study.
Medicina (Kaunas)
June 2024
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Injuries represent a serious concern for football players, with a significant loss in terms of sport participation and long periods of rehabilitation. According to the 2019/20 UEFA Élite Club Injury Report, the average incidence of injuries during training is 2.8 per 1000 h of training, with an average absence from training of 20 days.
View Article and Find Full Text PDFMedicina (Kaunas)
May 2024
Nephrology and Dialysis Unit, Magna Graecia University Hospital, 88100 Catanzaro, Italy.
: Selenium deficiency represents a risk factor for the occurrence of severe diseases, such as acute kidney injury (AKI). Recently, selenoprotein-p1 (SEPP1), a selenium transporter, mainly released by the liver, has emerged as a promising plasmatic biomarker of AKI as a consequence of cardio-surgery operations. The aim of the present study was to investigate, on an in vitro model of hypoxia induced in renal tubular cells, HK-2, the effects of sodium selenite (NaSeO) and to evaluate the expression of SEPP1 as a marker of injury.
View Article and Find Full Text PDFChildren (Basel)
May 2024
Division of Paediatric Cardiology, Department of Women and Children's Health, University Hospital of Padua, 35128 Padua, Italy.
The complete transposition of the great arteries (C-TGA) is a congenital cardiac anomaly characterized by the reversal of the main arteries. Early detection and precise management are crucial for optimal outcomes. This review emphasizes the integral role of multimodal imaging, including fetal echocardiography, transthoracic echocardiography (TTE), cardiovascular magnetic resonance (CMR), and cardiac computed tomography (CCT) in the diagnosis, treatment planning, and long-term follow-up of C-TGA.
View Article and Find Full Text PDFEur J Heart Fail
August 2024
Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes.
Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction.
Healthcare (Basel)
June 2024
Clinical and Experimental Medicine Department, Magna Graecia University, 88100 Catanzaro, Italy.
This review aims to analyze the effectiveness of motivational interviewing (MI) in enhancing therapeutic adherence and compliance in adult patients with inflammatory bowel disease (IBD), especially considering the disruptions caused by the COVID-19 pandemic. IBD, which includes conditions such as ulcerative colitis and Crohn's disease, affects over 10 million people globally. It significantly impacts both physical and psychological well-being, leading to challenges in therapeutic adherence.
View Article and Find Full Text PDF